Supplementary Methods

The preprocessing step for transcriptome data
For identifying tumor metabolism-associated gene coexpression network module, we made the training set with two microarray datasets from Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/) [1] . A microarray dataset with 18 F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) image data (accession number GSE28827 [2, 3] ) was included in the training set. Because GSE28827 includes few lung adenocarcinoma (LUAD) samples for conducting gene coexpression network analysis, we merged additional microarray dataset (accession number GSE31210 [4, 5] ). The normalized gene expression data of GSE28827 was downloaded using 'GEOquery' R package [6] . The raw gene expression data of GSE31210 was downloaded from the Gene Expression Omnibus data repository and called and normalized using the robust multichip average method using the 'affy' R package [7] . Since two datasets included multiple histologic types of non-small cell lung cancer, only LUAD samples were extracted for further preprocessing step. On a studyby-study basis, we removed invalid and duplicated probe sets by 'featureFilter' function in 'genefilter' R package [8] , and mapped array probe sets for the respective gene symbols. As we combined microarray data from different studies, we performed additional normalization using Combat algorithm in order to eliminate potential batch effect [9] . Lastly, to remove poor quality probes, we filtered out probe sets with low expression level (signal intensity < log2(100) in at least 25% of samples within at least one study) and low variability (interquartile range < 0.75). As a result, the training set contained 4010 genes from 246 LUAD samples including 20 samples with available FDG PET image.
For validation of the tumor metabolism-associated gene coexpression network modules, we used mRNA transcriptome data of LUAD from The Cancer Genome Atlas projects (TCGA) [10] . Using 'TCGABiolinks' R package [11] , we downloaded the level three RNA 
FDG PET/CT Data and Image Processing
In this study, we used FDG-PET/CT data of both training and validation sets provided by
The Cancer Imaging Archive [2, 12, 13] . We identified 20 and 17 patients having both transcriptome and FDG PET data available from the training and validation set, respectively.
For the training set (GSE28827), FDG was injected with a dose between 370 and 629 MBq depending on patients' weight. Scans were acquired by using a Discovery STE or LS PET/CT scanner (GE Healthcare) (section thicknesses, between 3 and 5 mm) with an iterative algorithm (ordered subset expectation maximization, OSEM). For the validation set (TCGA data), patients were administered mean 579.5 MBq (range: 518-724 MBq) FDG and images were acquired 60 minutes after administration. PET data were reconstructed by an iterative algorithm (OSEM). The acquisition and reconstruction parameters such as matrix size were different according to the imaging protocol of institute.
To characterize tumor metabolism, the maximum standardized uptake value was calculated.
A manually drawn spherical volume-of-interest around the tumor lesion was used for measuring maximum standardized uptake value. Image parameters were obtained by Metavol package [14] .
Gene ontology enrichment analysis
The enrichment of the gene ontology terms in tumor metabolism-associated module was evaluated based on the hypergeometric test using 'clusterProfiler' R package [15] . The gene ontology biological process terms at false discovery rate under < 0.05 in each tumor metabolism-associated module were regarded as significantly enriched terms.
LUAD molecular subtypes classification
The LUAD centroid subtypes (bronchioid, magnoid and squamoid) were assigned to all samples of TCGA [16] . Previously published classifier employed the nearest centroid classification based on 506 genes, which included several missing gene expression data in TCGA samples. Thus, for subtype classification, common genes of the classifier and TCGA samples were selected and the Pearson correlation was used as the similarity metric. A subtype with the maximum correlation coefficient was assigned to each sample as the previous TCGA study [10] .
Glucose metabolism signatures
Tumor metabolism index (TMI) was compared with gene signatures representing glucose metabolism. Glucose metabolism signatures were obtained by two different methods. Firstly, mean expression value of manually selected genes associated with glycolysis and gluconeogenesis was used as a metabolic signature [17] . Secondly, we used Reactome to select genes of glycolysis pathway [18] . To obtain enrichment score, we used single sample gene set enrichment analysis (ssGSEA) which provide pathway activity for each sample [19] .
The output of ssGSEA was normalized by z-score across samples and compared with TMI.
The Spearman's method was used for the correlation analysis.
Validation in an independent cohort
To verify the association between immune landscape, tumor metabolism, and prognosis, the analyses were additionally performed in an independent lung adenocarcinoma cohort [20] (GSE41271). The normalized gene expression data of GSE41271 was downloaded and TMI and cell type enrichment scores of all lung adenocarcinoma samples were calculated by the trained model, and xCell [21] , respectively. To define the clusters based on TCGA data, we obtained centers of each cluster from cell types enrichment scores of TCGA data. We calculated Euclidean distance between cell types enrichment score of each sample of the independent data and center of each cluster, and then assigned the cluster with the lowest distance to each sample. TMI and ImmuneScore of clusters were compared by one-way ANOVA followed by post hoc Tukey's test. The association of overall survival and variables including TMI, ImmuneScore, and clusters was analyzed by the Cox regression analysis. The survival rate of the groups was depicted with the Kaplan-Meier's method and compared with the log-rank test. To define risk groups, TMI and ImmuneScore were dichotomized using the median value of each variable in the validation set. The subjects with high ImmuneScore showed significantly better prognosis. (E) A trend of poor prognosis in high TMI tumors was found as results of TCGA data.
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